Evercore’s ( EVR Quick Quote EVR - Free Report) third-quarter 2020 earnings release, shares of the company have rallied around 6%. The company reported adjusted earnings per share of $1.11, handily beating the Zacks Consensus Estimate of 37 cents on solid underwriting fees. However, results were down 12% from the prior-year quarter’s $1.26 per share. The quarterly results reflect higher assets under management (AUM) and stable revenues. In addition, liquidity position was consistently strong. However, escalating expenses was a major drag. Including certain one-time items, on a GAAP basis, net income available to common shareholders was $42.6 million or $1.01 per share compared with the $43.3 million or $1.01 per share reported in the year-ago quarter. Revenues Stable, Expenses Rise
Net revenues remained flat year over year at $408.5 million in the reported quarter. Hike in underwriting fees and other revenues were offset by lower advisory fees and commissions and related fees. The figure surpassed the Zacks Consensus Estimate of $335.7 million. On a GAAP basis, net revenues were $402.5 million, almost unchanged.
Total expenses flared up 2.2% to $330.9 million from the prior-year quarter. This upswing mainly stemmed from rise in employee compensation and benefits expenses. Adjusted compensation ratio was 63.6%, up from the year-earlier quarter’s 58%. Adjusted operating margin came in at 19% compared with the prior-year quarter’s 20.8%. Quarterly Segment Performance (Adjusted) Investment Banking: Net revenues declined marginally year over year to $390.3 million. Also, operating income slid 11% to $71.6 million. Advisory client transactions were 206,000, down 3% year over year. Notably, underwriting revenues of $66.5 million in the quarter more than doubled compared with the prior-year period. Investment Management: Net revenues were $18.2 million, up 11% from the prior year’s comparable quarter. Operating income was $6.1 million, up 37% year over year. Additionally, an AUM of $10.9 million was reported in the third quarter, up 7% year over year. Balance-Sheet Position
As of Sep 30, 2020, cash, cash equivalents, marketable securities and certificates of deposit totaled $1.1 billion. Moreover, current assets exceeded current liabilities by $1 billion as of the same date.
During the reported quarter, the company repurchased 16,000 shares from employees for the net settlement of stock-based compensation awards at an average price of $58.37 per share.
Concurrent with earnings, Evercore’s board of directors announced a common stock quarterly dividend of 61 cents per share, up 5% from the prior payout. The dividend will be paid on Dec 11, to shareholders of record as of Nov 27, 2020. Our Viewpoint
Evercore displayed an impressive performance during the July-September quarter. Its top-line strength displays earnings stability. Apart from this, the company’s strategic initiatives to bolster its investment banking segment bode well. Though escalating expenses are a concern, it is well poised to undertake any opportunistic expansion given its sound liquidity position.
Currently, Evercore flaunts a Zacks Rank #1 (Strong Buy). You can see
. the complete list of today’s Zacks #1 Rank stocks here
Performance of Other Banks Charles Schwab’s ( SCHW Quick Quote SCHW - Free Report) third-quarter 2020 adjusted earnings of 51 cents per share beat the Zacks Consensus Estimate of 47 cents. However, the bottom line decreased 27% from the prior-year quarter. Results reflect solid client assets balance and a rise in new brokerage accounts. These were driven by solid client activity in the coronavirus pandemic-induced volatile markets. However, lower revenues and an increase in expenses acted as headwinds. We now look forward to the upcoming quarterly results of Raymond James Financial, Inc. ( RJF Quick Quote RJF - Free Report) and LPL Financial Holdings Inc. ( LPLA Quick Quote LPLA - Free Report) . Raymond James and LPL Financial are slated to release results for the September-end quarter on Oct 28 and Oct 29, respectively. Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>